Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Official Title

A Phase 1/2, Multicentre, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation

Summary:

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of FT-2102 (single agent) and FT-2102 + azacitidine (combination agent) administered via one or more intermittent dosing schedules followed by a dose expansion part. The dose expansion part will enroll patients in up to 5 expansion cohorts, exploring single-agent FT-2102 activity as well as combination activity with azacitidine or cytarabine. Following the completion of the relevant Phase 1 cohorts, Phase 2 will begin enrollment. Patients will be enrolled across 6 different cohorts, examining the effect of FT-2102 (as a single agent) and FT-2102 + azacitidine (combination) on various AML/MDS disease states.

Trial Description

Primary Outcome:

  • Maximum Tolerated Doses (MTDs) or Maximum Evaluated Doses (MEDs) [Phase 1]
  • Number of Participants with a Dose Limiting Toxicity (DLT) [Phase 1]
  • Doses recommended for future studies [Phase 1]
  • Complete Response (CR, CRi, MLFS, Marrow CR) Rate of FT-2102 single-agent or in combination with Azacitidine in patients with AML/MDS [Phase 2]
Secondary Outcome:
  • Area under the plasma concentration versus time curve (AUC) [Phase 1 and Phase 2]
  • Peak Plasma Concentration (Cmax) [Phase 1 and Phase 2]
  • Time of peak plasma concentration Tmax [Phase 1 and Phase 2]
  • Time for half of the drug to be absent in blood stream following dose (T 1/2) [Phase 1 and Phase 2]
  • Rate at which drug is removed from blood stream (CL/F) [Phase 1 and Phase 2]
  • Rate of drug distribution within the blood stream (Vd/F) [Phase 1 and Phase 2]
  • Evidence of antileukemic or antimyelodysplastic activity of FT-2102 as determined by CR, CRi, MLFS, Marrow CR, PR, and SD as a single-agent or in combination with azacitidine or cytarabine [Phase 1]
  • Incidence and severity of adverse events, clinical laboratory abnormalities, and changes in ECG parameters as assessed by CTCAE v4.0 as a single-agent or in combination with azacitidine [Phase 2]
  • Additional measures of antileukemic or antimyelodysplastic activity as determined by CRh, Overall Response (OR), and Stable Disease of FT-2102 alone or in combination with azacitidine [Phase 2]
  • Time to Response (TTR) [Phase 2]
  • Duration of Response (DOR) [Phase 2]
  • Event-Free Survival (EFS) [Phase 2]
  • Overall Survival (OS) [Phase 2]

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society